肌层浸润性膀胱癌新辅助化疗后临床完全缓解患者的非肌层浸润性复发与监测管理
本研究回顾性分析61例接受顺铂为基础新辅助化疗后达临床完全缓解(cCR)的肌层浸润性膀胱癌患者,均纳入严格主动监测方案。中位随访28.3个月,28例出现共46次非肌层浸润性复发,其中高级别占80%,多数接受卡介苗诱导治疗;非肌层浸润性复发与后续肌层浸润或转移无关联。
要点
- cCR患者非肌层浸润性复发率高,但多数可安全保留膀胱治疗。
- 高级别复发占多数,60%接受卡介苗诱导治疗。
- 非肌层浸润性复发未增加肌层浸润或转移风险。
核心结论
- 新辅助化疗后达cCR的肌层浸润性膀胱癌患者非肌层浸润性复发率高,但多数可安全采用保留膀胱治疗。
研究设计与样本
- 回顾性分析前瞻性维护数据库,纳入61例接受顺铂为基础新辅助化疗且经内镜切除、尿细胞学和横断面成像判定为cCR的患者,并执行严格主动监测方案。
主要发现
- 中位随访28.3个月,28例患者发生非肌层浸润性复发,中位复发次数为1次,共46次复发。
- 46次复发中低级别9次(20%),高级别37次(80%)。
- 37次高级别复发中多数(60%)接受卡介苗诱导治疗。
- 非肌层浸润性复发与后续肌层浸润性复发或转移无关联。
- 配对肿瘤样本基因组分析显示1例存在克隆相关性,另1例提示可能为癌前尿路上皮场效应。
临床怎么用
- 对新辅助化疗后cCR的肌层浸润性膀胱癌患者应执行严格主动监测方案,及时发现并处理非肌层浸润性复发,多数患者可避免早期根治性膀胱切除。
局限性
- 回顾性设计,样本量较小(61例),随访时间有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Many patients are medically unfit for or refuse radical cystectomy. Few postchemotherapy bladder-sparing active surveillance programs have reported on nonmuscle-invasive recurrences and treatment outcomes. In this study, we present data on nonmuscle-invasive recurrences and their management in this population. MATERIALS AND METHODS: This is a retrospective review of a prospectively maintained database. All patients received cisplatin-based neoadjuvant chemotherapy and were determined to have a clinical complete response (cCR) based on negative endoscopic resection, urine cytology, and cross-sectional imaging. Patient data were entered into a strict active surveillance protocol. Primary outcomes of interest were number of nonmuscle-invasive recurrences, grade and stage, and treatment. Secondary outcomes of interest were nonmuscle-invasive treatment response rate and muscle-invasive and metastatic recurrence rate. RESULTS: A total of 61 cCR patients were identified. In total, 28 patients experienced a median of 1 nonmuscle-invasive recurrence over a median follow-up of 28.3 months. There were a total of 46 nonmuscle-invasive recurrences, including 9 (20%) low-grade recurrences and 37 (80%) high-grade recurrences. Of the 37 high-grade recurrences, the majority (60%) were treated with Bacillus Calmette-Guérin induction. Nonmuscle-invasive recurrence was not associated with later muscle-invasive recurrence or metastasis. Genomic analysis of paired tumor samples demonstrated clonal relatedness in one patient sample while another sample demonstrated a likely precancerous urothelial field effect. CONCLUSIONS: There is a high rate of nonmuscle-invasive recurrences in patients who achieve cCR to neoadjuvant chemotherapy. However, most of these patients may be safely managed with bladder-preserving treatments. These findings emphasize the importance of vigilant surveillance protocols and appropriate patient selection.
引用
- Joffe BI, Pingle SR, Laplaca C, et al. Nonmuscle-Invasive Recurrence and Management During Surveillance in Patients with Muscle-Invasive Bladder Cancer Who Achieve Clinical Complete Response to Neoadjuvant Chemotherapy. J Urol. 2026. PMID: 42647819. doi:10.1097/JU.0000000000005278
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。